Founders & management

Founded in 2005, by Alexandre TOKAY, CEO, and Dr. Michel KHRESTCHATISKY, Scientific Advisor, VECT-HORUS is a spin-off of the NICN UMR7259 (CNRS and Aix-Marseille University) now Institute for NeuroPhysiopathology (INP) directed by Dr. Michel KHRESTCHATISKY (UMR7051, CNRS AMU). Based in Marseille, France, the company has 37 employees, mostly in R&D. To strengthen its leadership, the company has brought together a team of exceptional leaders from the Pharma/Biotech industry.

Alexandre TOKAY 
Alexandre TOKAY
CEO and co-founder
Michel KHRESTCHATISKY 
Michel KHRESTCHATISKY
Co-founder and scientific counsel
Jamal TEMSAMANI 
Jamal TEMSAMANI
Chief Business Officer
Jean-Manuel PEAN 
Jean-Manuel PEAN
Chief Scientific Officer

Scientific advisory board

Six renowned scientists and experts in neuropharmacology, oncology and molecular engineering bring their expertise to VECT-HORUS.

Pr. Pascal HAMMEL 
Pr. Pascal HAMMEL
MD
Pr. Frédéric COURBON 
Pr. Frédéric COURBON
PhD
Jean-Pierre BENOIT 
Jean-Pierre BENOIT
PharmD, PhD
Julia ALTERMAN 
Julia ALTERMAN
PhD
Frederic MATONTI 
Frederic MATONTI
MD PhD FEBO
Xavier Declèves 
Xavier Declèves
Professor of Pharmacokinetics, PharmD, PhD

Financial & Academic Partners

Financial partners

VECT-HORUS continues its funding strategy with historic shareholders and also new entrants to grant the Company significant financial resources to carry out its research and development programs and leverage with public research grants.

bpifrance Crédit Agricole
Protisvalor Financière tuileries co-invest

Vect-Horus received the agreement of Région Sud - Provence-Alpes-Côte d’Azur for a non-dilutive grant of more than 1 M€ from the REACT-EU program. This project is financed with the assistance of the European Union with the European Regional Development Fund in response to the COVID-19 pandemic.

Vect-Horus plans to optimize its R&D and production equipment to accelerate the demonstration of its technology VECTrans® and to ensure its development on a larger scale to meet the needs of its Pharma/Biotech partners and new challenges in therapy, in particular, in the development of innovative therapeutic approaches based on nucleic acids (siRNAs, ASOs, mRNAs) which require targeting and cellular transport technologies.

Academic partners

Close collaborations with top academic research centers: AMU, CEA, CERIMED, CNRS, INP, INSERM

Aix-Marseille université CERIMED
CNRS CEA INSERM